Affiliation
University of Manchester, Institute of Cancer Sciences, The Christie Hospital, Manchester Cancer Research Centre, Manchester Academic Health Sciences Centre , Manchester M20 4BX , UK +44 0 161 446 8110 ; +44 0 161 446 8001 ; tmi@manchester.ac.uk.Issue Date
2014-10
Metadata
Show full item recordAbstract
The anti-CD20 mAb rituximab has revolutionized the treatment of B-cell malignancies, improving outcome for patients. Despite these improvements, the majority of patients still relapse and become refractory to rituximab. Further efforts to improve anti-CD20 mAb efficacy have recently focused on obinutuzumab /GA101, a novel anti-CD20 mAb glycoengineered to display enhanced Fc-mediated effector mechanisms and induce direct cell death.Citation
Update on obinutuzumab in the treatment of B-cell malignancies. 2014, 14 (10):1507-17 Expert Opin Biol TherJournal
Expert Opinion on Biological TherapyDOI
10.1517/14712598.2014.948414PubMed ID
25190612Type
ArticleLanguage
enISSN
1744-7682ae974a485f413a2113503eed53cd6c53
10.1517/14712598.2014.948414
Scopus Count
Collections
Related articles
- Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.
- Authors: Shah A
- Issue date: 2014 Oct
- Obinutuzumab for the treatment of chronic lymphocytic leukemia.
- Authors: Rogers KA, Jones JA
- Issue date: 2014 Jun
- Obinutuzumab for B-cell malignancies.
- Authors: Owen CJ, Stewart DA
- Issue date: 2014 Aug
- Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody.
- Authors: Goede V, Klein C, Stilgenbauer S
- Issue date: 2015
- Obinutuzumab in hematologic malignancies: lessons learned to date.
- Authors: Illidge T, Klein C, Sehn LH, Davies A, Salles G, Cartron G
- Issue date: 2015 Nov